Evome Medical posts FY2023 preliminary revenue C$62.6M, positive Adj EBITDA C$852K

EVOME MEDICAL TECHNOLOGIES INC.

Revenue C$62.6M, gross margin C$22.5M (36% of sales); Adjusted EBITDA positive C$852K.
CEO Seckler states turnaround completed after H1 losses; two consecutive quarters of positive Adj EBITDA.
Full FY2023 financial statements (10-K) to be filed April 16, 2024.
Plans to reduce debt by divesting non-core units; launched RST product; SpaceTek Knee expected late 2024.
Fourth-quarter strength drove full-year positive EBITDA; first quarter 2024 improvements continuing.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EVOME MEDICAL TECHNOLOGIES INC. reported preliminary financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: preliminary results

Exact text from the filing

On April 1, 2024, Evome Medical Technologies Inc. issued a press release containing certain preliminary annual financial results for the year ended December 31, 2023.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001062993-24-007571

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.